Amifampridine
- TRADE NAME: Firdapse (Catalyst Pharma Inc)
- INDICATIONS: indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
- CLASS: Potassium channel blocker
- HALF-LIFE: 1.8–2.5 hours
FDA APPROVAL DATE: 11/28/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
no data on associated risk
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric